Valneva SE announced that the FDA and the U.S. Centers for Disease Control and Prevention (CDC), in a joint communication to the medical community, have recommended a pause… read more.
Johnson & Johnson MedTech announced that results from the TARGET study have been published by CHEST Journal. This landmark study demonstrated that clinicians were able to reach small… read more.
NICE (UK): Molnupiravir is recommended as an option for treating mild to moderate COVID‑19 in adults who have a positive SARS‑CoV‑2 test, only if: i) they have 1… read more.
Atara Biotherapeutics, Inc. a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases,… read more.
BeiGene, Ltd announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA issued a positive opinion recommending approval of Tevimbra (tislelizumab), in combination with gemcitabine… read more.
Roche announced the launch of its Elecsys PRO-C3 test, a new diagnostic solution designed to assess the severity of liver fibrosis in patients showing signs of metabolic dysfunction–associated… read more.
NICE (UK): NICE is unable to make a recommendation on omaveloxolone (Skyclarys) for treating Friedreich’s ataxia in people 16 years and over. This is because Biogen withdrew its… read more.
NICE (UK): Fenfluramine is recommended as an option for treating seizures associated with Lennox–Gastaut syndrome (LGS), as an add-on to other antiseizure medicines, for people 2 years and over…. read more.
NICE(UK): Brentuximab vedotin plus doxorubicin, dacarbazine and vinblastine is recommended, within its marketing authorisation, as an option for untreated stage 3 or 4 CD30‑positive Hodgkin lymphoma in adults. It can… read more.
Pfizer Inc. announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of… read more.
Medtronic plc announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a… read more.
NICE(UK): Cenobamate is recommended as an option as an add-on treatment for focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
